Cargando…
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
BACKGROUND: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CS...
Autores principales: | Karpova, Darja, Bräuninger, Susanne, Wiercinska, Eliza, Krämer, Ariane, Stock, Belinda, Graff, Jochen, Martin, Hans, Wach, Achim, Escot, Christophe, Douglas, Garry, Romagnoli, Barbara, Chevalier, Eric, Dembowski, Klaus, Hooftman, Leon, Bonig, Halvard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209880/ https://www.ncbi.nlm.nih.gov/pubmed/28049490 http://dx.doi.org/10.1186/s12967-016-1107-2 |
Ejemplares similares
-
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013) -
Hematopoietic-Extrinsic Cues Dictate Circadian Redistribution of Mature and Immature Hematopoietic Cells in Blood and Spleen
por: Stenzinger, Miriam, et al.
Publicado: (2019) -
Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice
por: Danner, Eva, et al.
Publicado: (2019) -
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
por: Wiercinska, Eliza, et al.
Publicado: (2021) -
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL
por: Sison, Edward Allan R., et al.
Publicado: (2015)